loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Mitapivat Sulfate

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Mitapivat Sulfate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Agios To Receive $1.1B In Milestone Payments For Vorasidenib Approval
    Agios To Receive $1.1B In Milestone Payments For Vorasidenib Approval

    06 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/06/2925573/31990/en/Agios-to-Receive-1-1-Billion-in-Milestone-Payments-Following-FDA-Approval-of-Vorasidenib.html

    GLOBENEWSWIRE
    06 Aug 2024
    Share Share
    Agios Announces Phase 3 ACTIVATE-KidsT Study Results
    Agios Announces Phase 3 ACTIVATE-KidsT Study Results

    01 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/01/2922579/31990/en/Agios-Announces-Results-from-Phase-3-ACTIVATE-KidsT-Study-of-Mitapivat-in-Children-with-PK-Deficiency-Who-Are-Regularly-Transfused.html

    GLOBENEWSWIRE
    01 Aug 2024
    Share Share
    Agios Presents Phase 3 Mitapivat Results In Thalassemia At EHA
    Agios Presents Phase 3 Mitapivat Results In Thalassemia At EHA

    15 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/15/2899255/31990/en/Agios-Presents-Positive-Results-from-Phase-3-ENERGIZE-Study-of-Mitapivat-in-Non-Transfusion-Dependent-Thalassemia-in-Plenary-Session-at-the-European-Hematology-Association-2024-Hyb.html

    GLOBENEWSWIRE
    15 Jun 2024
    Share Share
    Agios' Mitapivat Met Endpoints In Transfusion-Dependent Thalassemias
    Agios' Mitapivat Met Endpoints In Transfusion-Dependent Thalassemias

    03 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/03/2892080/31990/en/Agios-Announces-Phase-3-ENERGIZE-T-Study-of-Mitapivat-Met-Primary-Endpoint-and-All-Key-Secondary-Endpoints-in-Adults-with-Transfusion-Dependent-Alpha-or-Beta-Thalassemia.html

    GLOBENEWSWIRE
    03 Jun 2024
    Share Share
    Agios Pharmaceuticals' blood disorder drug succeeds in late-stage study
    Agios Pharmaceuticals' blood disorder drug succeeds in late-stage study

    03 Jun 2024

    // Mariam Sunny REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/agios-pharmaceuticals-blood-disorder-drug-succeeds-late-stage-study-2024-06-03/

    Mariam Sunny REUTERS
    03 Jun 2024
    Share Share
    Agios To Present Rare Blood Disorder Data At EHA 2024
    Agios To Present Rare Blood Disorder Data At EHA 2024

    14 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/14/2881554/31990/en/Agios-Pharmaceuticals-to-Present-Clinical-and-Translational-Data-in-Rare-Blood-Disorders-at-European-Hematology-Association-2024-Hybrid-Congress.html

    GLOBENEWSWIRE
    14 May 2024
    Share Share